What is it about?
This rebuttal letter highlights key limitations of the report by Kulkarni AV et al on the safety of a widely prescribed Ayurveda herb Tinospora Cordifolia (Giloy) that appeared in the January 2022 edition of Hepatology Communications to help understand the true value of the report
Featured Image
Photo by Sushobhan Badhai on Unsplash
Why is it important?
A one-sided report got published in a reputable journal and subsequently gained traction in popular local news media outlets in India. The authors made several sweeping claims in the article about the lack of safety of a widely used herb in Ayurveda based on one poorly designed retrospective study. It is was therefore important to provide the readers of the report a proper context and highlight its limitations so as to be able to better appreciate its true value and draw valid inferences.
Perspectives
As an Ayurveda practitioner for over 3 decades and having worked closely with allopathic colleagues, I am deeply appreciative and respectful of the vital role played by modern medicine in the healthcare delivery to the society at large. At the same time, I firmly believe that is imperative for each party to acknowledge the respective and mutually exclusive practice rights of the other to better serve the society in a country like India that has a complex multi-modal healthcare system.
Gangadharan G G
Ramaiah Indic Specialty Ayurveda Restoration Hospital (RISA)
Read the Original
This page is a summary of: Response to
Tinospora cordifolia
(Giloy)‐induced liver injury during the COVID‐19 pandemic—Multicenter nationwide study from India, Hepatology Communications, May 2022, Wiley,
DOI: 10.1002/hep4.1986.
You can read the full text:
Contributors
The following have contributed to this page
